Royer Biomedical, Inc.
4580 F Mack Ave.
Frederick, MD 216587
Phone: (410) 267-8811
Fax: (410) 267-8235
Email: [email protected]
Garfield Royer, Ph.D.,
Chairman & President
Richard Voss, VP, Human
Health & Business Development
Joseph Manda, Ph.D., VP,
Jerry Hook, Ph.D., Sr.
The Company was founded in 1996 by Dr. Garfield Royer. A Ph.D.
biochemist with both academic and commercial experience, Dr. Royer
believes that his research has produced chemical compositions
which are superior versus other drug delivery technologies
currently in use. The Company is based in Frederick, Md. and
currently has 6 full-time employees and contracted staff.
PRODUCT LINE OR SERVICE
The Company currently has one commercially available product-
Silvadex-SR. Other applications in development are as
follows:Veterinary Applications:Iverdex Equine*,Amidex SR*,Enroflex
Canine*,Cis-Pt/SRL*,Iverdex Canine, and Silvadex Otic. Human
Applications: Amidex SR, Contraceptive Vaccine*, and Anti-cancer
Vaccine. (*indicates clinical trials in 2001)
Information regarding the relevant U.S. markets within human
health are as follows (all amounts in millions): Cancer Vaccines-
$800, Other Vaccines- $1,000, Localized Infections- $450,
Prophylactic use of antibiotics- $200, Therapeutic and regulatory
proteins and polypeptides- $10,000 U.S. market opportunity for
Royer's proposed animal health products totals over $350 million.
Matrix III is highly effective at providing controlled, and
often highly targeted, releases of drugs over a broad range of
time spans. Potential applications include protein and small
molecule based therapeutics, and vaccines.
MARKETING/SALES & DISTRIBUTION
The Company anticipates developing commercialized products with
pharmaceutical company partners. It anticipates that, with their
already established marketing and distribution channels, its
partner will manage and execute the consumer sales strategies for
The Company intends to outsource or license the manufacturing
of most, if not all, of its applications to GMP contract
manufacturers and strategic partners. With funding from Md. Bio,
the Company has been investigating the feasibility of developing a
manufacturing facility to manufacture its Matrix III formulation
and possibly certain of its veterinary applications.
The following are known public and private companies which have
or may have technology which is competitive with that of Royer
Biomedical: Alkermes, Atrix, Alza, DepoTech, Elan, Guilford
Pharmaceuticals, Macromed, OraPharma, Matrix, Shire, and